A Phase 2 interventional study of Placebo and CD11301 0.03% in Cutaneous T Cell Lymphoma, sponsored by Galderma R&D. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States — 33 open to participants now, 45 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · United States.
Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, this one is the 52nd largest by enrollment of the 334 interventional ones that give a count, is one of 12 that started in 2017, is one of 114 in phase 2, and was the 376th registered.
554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.
Browse Lymphoma, T-Cell, Cutaneous studies →33 of the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
Seda S. Tolu · Sites in United States
Ages 18–95
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
434 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 201 · Phase 2 157 · Phase 3 28 · Phase 4 5
First in 1988; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 35 across 405 interventional studies indexed under Lymphoma, T-Cell, Cutaneous.
Median enrollment 33 across the 334 interventional studies, 60 across the 41 observational. Of the 359 that completed or were terminated, 115 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 434 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Galderma Group AG has 1 study filed under Lymphoma, T-Cell, Cutaneous — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma, T-Cell, Cutaneous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05996185Yale UniversityStudy of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | 2026-11 |
| NCT05956041University of Michigan Rogel Cancer CenterPembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | 2026-12 |
| NCT06860880UNC Lineberger Comprehensive Cancer CenterCombating Cancer-Related Fatigue: A Personalized Supportive Care Program | 2026-12-31 |
| NCT05296304Memorial Sloan Kettering Cancer CenterA Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | 2027-03 |
| NCT05680558Columbia UniversityPhotopheresis in Early-stage Mycosis Fungoides | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
To assess the efficacy and safety of two concentrations (0.03% and 0.06%) of CD11301 gel in the treatment of early stage CTCL (stage IA, IB, or IIA) versus placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
Drug: CD11301 0.06%
Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
Drug: CD11301 0.03%
Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
Drug: Placebo · Drug: CD11301 0.03%
Non active ingredients of CD11301
Drug page: ResiquimodStudies of ResiquimodResiquimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Topical Gel
Drug page: ResiquimodStudies of ResiquimodResiquimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Topical Gel
Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12
Overall response is defined as the number of participants that achieved a complete response (CR) or partial response (PR) as assessed by mCAILS. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity. Complete response is defined as a 100% decrease from baseline i.e. score of '0' on the mCAILS scale. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline.
Time frame: Week 12
Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12
OR is defined as the number of participants that achieved a complete response or partial response as assessed by mSWAT. mSWAT composite score involved the direct assessment of the BSA of each type of lesion (palm plus fingers of the participant= approximately 1% BSA) in each of 12 areas (Head, Neck, Anterior trunk, Arms, Forearms, Hands, Posterior trunk, Buttocks, Thighs, Legs, Feet, Groin) of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch = 1, plaque = 2, and tumor = 3 or 4) and generating a sum of the subtotals of each lesion subtype. mSWAT score (0=no lesions; 400= lesions covering all areas). Complete response is defined as a 100% decrease from baseline. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline, and with a tumor subscore of zero (no tumor).
Time frame: Week 12
Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score
Time to overall response (CR or PR) is the number of days from the start of drug application to the first documentation of objective response assessed by mCAILS Score. The 25th, 50th, and 75th percentiles were presented along with 95% confidence intervals using the log-log transformation. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.
Time frame: Up to Week 36
Duration of Overall Response (Complete Response or Partial Response) Based on mCAILS Score
The duration of overall response (complete or partial) of the target treated lesions based on the mCAILS score was calculated in days as: (date of first non-response after responding) - (date of response) + 1. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.
Time frame: Up to Week 36
Time to Progressive Disease Using mSWAT
Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, Nadir is defined as the lowest skin score (best response).
Time frame: Up to Week 36
Change From Baseline in Skindex-29 Survey Results at Week 12, 24 and 36
Participants answered 30 questions as part of the Skindex-29 survey. A composite score and 3 sub scores were calculated from the results. Item 18 of the survey was not used in any scoring. First, answers to each item were given a numeric value: Never = 0; Rarely = 25; Sometimes = 50; Often = 75; All the time = 100. The items used to calculate each subscore were: Emotions: 3, 6, 9, 12, 13, 15, 21, 23, 26, and 28 (10 items), Symptoms: 1, 7, 10, 16, 19, 24, and 27 (7 items), Functioning: 2, 4, 5, 8, 11, 14, 17, 20, 22, 25, 29, and 30 (12 items). The composite score is the average of the 3 sub scores ranging from 0 (no effect)-100 (maximum effect), higher score corresponds to lower quality of life.
Time frame: Week 12, 24 and Follow up (Week 36)
This study was conducted at 3 countries (France, Germany, USA) between 19 Dec 2017 to 17 Mar 2020. A total of 86 participants were randomized to 1 of the 3 treatment groups (placebo gel or CD11301 gel 0.03% or 0.06%) in a 1:1:1 ratio.
| Milestone | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Started | 30 | 28 | 28 |
| Participants treated | 30 | 28 | 27 |
| Completed | 17 | 15 | 15 |
| Not completed | 13 | 13 | 13 |
| Withdrew: Progressive disease | 6 | 3 | 4 |
| Withdrew: Adverse event | 7 | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 7 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Other | 0 | 1 | 2 |
Overall response is defined as the number of participants that achieved a complete response (CR) or partial response (PR) as assessed by mCAILS. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity. Complete response is defined as a 100% decrease from baseline i.e. score of '0' on the mCAILS scale. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline.
| Participants | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Complete Response | 0 | 2 | 0 |
| Partial Response | 4 | 5 | 1 |
OR is defined as the number of participants that achieved a complete response or partial response as assessed by mSWAT. mSWAT composite score involved the direct assessment of the BSA of each type of lesion (palm plus fingers of the participant= approximately 1% BSA) in each of 12 areas (Head, Neck, Anterior trunk, Arms, Forearms, Hands, Posterior trunk, Buttocks, Thighs, Legs, Feet, Groin) of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch = 1, plaque = 2, and tumor = 3 or 4) and generating a sum of the subtotals of each lesion subtype. mSWAT score (0=no lesions; 400= lesions covering all areas). Complete response is defined as a 100% decrease from baseline. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline, and with a tumor subscore of zero (no tumor).
| Participants | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Complete Response | 0 | 0 | 0 |
| Partial Response | 6 | 4 | 2 |
Time to overall response (CR or PR) is the number of days from the start of drug application to the first documentation of objective response assessed by mCAILS Score. The 25th, 50th, and 75th percentiles were presented along with 95% confidence intervals using the log-log transformation. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.
| Days | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| 25th (95% CI) | 169 (84.0 to 169.0) | 85 (83.0 to 174.0) | NA (85.0 to NA) |
| 50th (95% CI) | 197 (169.0 to 257) | NA (169.0 to NA) | NA (NA to NA) |
| 75th (95% CI) | 257 (197.0 to 257) | NA (NA to NA) | NA (NA to NA) |
The duration of overall response (complete or partial) of the target treated lesions based on the mCAILS score was calculated in days as: (date of first non-response after responding) - (date of response) + 1. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.
| Days | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| 25th (95% CI) | 133 (29.0 to 141.0) | NA (38.0 to NA) | NA (NA to NA) |
| 50th (95% CI) | 141 (133.0 to NA) | NA (38.0 to NA) | NA (NA to NA) |
| 75th (95% CI) | NA (133.0 to NA) | NA (NA to NA) | NA (NA to NA) |
Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, Nadir is defined as the lowest skin score (best response).
| Days | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| 25th (95% CI) | NA (170.0 to NA) | 191 (85.0 to NA) | 93 (85.0 to 93.0) |
| 50th (95% CI) | NA (NA to NA) | NA (NA to NA) | 93 (NA to NA) |
| 75th (95% CI) | NA (NA to NA) | NA (NA to NA) | 93 (NA to NA) |
Participants answered 30 questions as part of the Skindex-29 survey. A composite score and 3 sub scores were calculated from the results. Item 18 of the survey was not used in any scoring. First, answers to each item were given a numeric value: Never = 0; Rarely = 25; Sometimes = 50; Often = 75; All the time = 100. The items used to calculate each subscore were: Emotions: 3, 6, 9, 12, 13, 15, 21, 23, 26, and 28 (10 items), Symptoms: 1, 7, 10, 16, 19, 24, and 27 (7 items), Functioning: 2, 4, 5, 8, 11, 14, 17, 20, 22, 25, 29, and 30 (12 items). The composite score is the average of the 3 sub scores ranging from 0 (no effect)-100 (maximum effect), higher score corresponds to lower quality of life.
| score on scale | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Week 12 | 1.93 ± 12.408 | -0.27 ± 8.583 | -1.58 ± 13.243 |
| Week 24 | -2.16 ± 11.651 | -3.36 ± 9.816 | 0.58 ± 16.059 |
| Week 36 | -3.30 ± 14.838 | -3.22 ± 8.340 | -0.34 ± 14.081 |
Collected over From start of the study drug administration up to end of the study (Week 72).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD11301 Gel 0.06% | 0/30 (0%) | 2/30 (6.7%) | 30/30 (100%) |
| CD11301 Gel 0.03% | 0/28 (0%) | 2/28 (7.1%) | 28/28 (100%) |
| Placebo | 1/27 (3.7%) | 1/27 (3.7%) | 27/27 (100%) |
| Event | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/28 | 1/27 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/28 | 1/27 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/28 | 1/27 |
| Metastases to muscleNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/28 | 1/27 |
| Papillary cystadenoma lymphomatosumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/28 | 0/27 |
| Sinus bradycardiaCardiac disorders | 0/30 | 1/28 | 0/27 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/30 | 0/28 | 0/27 |
| SciaticaNervous system disorders | 1/30 | 0/28 | 0/27 |
| Event | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo |
|---|---|---|---|
| Application site erosionGeneral disorders | 9/30 | 3/28 | 2/27 |
| Application site ulcerGeneral disorders | 8/30 | 8/28 | 2/27 |
| Application site pruritusGeneral disorders | 4/30 | 8/28 | 4/27 |
| Application site erythemaGeneral disorders | 7/30 | 5/28 | 2/27 |
| HeadacheNervous system disorders | 7/30 | 5/28 | 1/27 |
| Application site inflammationGeneral disorders | 0/30 | 6/28 | 1/27 |
| Application site painGeneral disorders | 6/30 | 3/28 | 2/27 |
| Influenza like illnessGeneral disorders | 6/30 | 3/28 | 2/27 |
| Mycosis fungoidesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/30 | 4/28 | 5/27 |
| PruritusSkin and subcutaneous tissue disorders | 2/30 | 3/28 | 5/27 |
Intent to treat (ITT) Population included all randomized participants.
| Age, Continuous(years) | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo | Total |
|---|---|---|---|---|
| Mean | 60.4 ± 14.43 | 56.8 ± 15.68 | 61.0 ± 14.21 | 59.5 ± 14.72 |
| Sex: Female, Male(Participants) | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 12 | 28 |
| Male | 22 | 20 | 16 | 58 |
| Ethnicity (NIH/OMB)(Participants) | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 | 4 |
| Not Hispanic or Latino | 29 | 27 | 26 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD11301 Gel 0.06% | CD11301 Gel 0.03% | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 28 | 27 | 24 | 79 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No intent to share information.
Ran from Dec 2017 to primary completion in Mar 2020, 26 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 47 phase 2 interventional studies under Lymphoma, T-Cell, Cutaneous, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 97. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resiquimod